Project description
Helping surgeons to stop excessive bleeding
In major surgery, excessive blood loss is associated with longer hospital stays, delayed recovery and increased mortality. Haemostatic agents can be used to control bleeding. However, most haemostats currently used by surgeons have lengthy preparation times, are difficult to apply and stick to surgical instruments limiting their suitable application. In this context, the EU-funded HEMOSNOW project will conduct the clinical study and upscale production to commercialise a unique haemostatic powder formulation capable of stopping minimum (oozing) and mild (pooling) bleeding (level 1 & 2 bleeding on the SPOTGRADE scale). It is a collagen-based powder that is ready to use and stops bleeding within 6 minutes.
Objective
Excessive blood loss during surgery is a major concern - 42% of all patients who experience excessive blood loss during surgery die. Excessive bleeding contributes to longer hospital stays and delayed post-operative recovery. This incurs costs for both hospitals and patients with increased operating room time estimated to cost €1,542 - €2,554/hour while increased hospital stay is estimated at €1,038/day. Conventional techniques used to control excessive bleeding such as electrocautery are not always feasible and are often restricted to accessible vessels of a minimum size. This limits their applicability and contributes to postoperative drainage and pain. Haemostatic agents are formulations designed to arrest bleeding by supplementing the normal haemostatic mechanism of the body. Most haemostats currently used by surgeons to control bleeding have lengthy preparation times, are difficult to apply and stick to surgical instruments which limits their suitable application. In response, Biom’up has developed HEMOSNOW, a unique haemostatic powder formulation capable of stopping level 1 & 2 bleeding on the SPOTGRADE scale (developed and patented by Biom’up to quantitatively determine bleeding from surgical wounds). This collagen-based powder is ready to use and stops bleeding within 6minutes. It will equip surgeons with an effective tool for rapid and effective haemostasis, reduce operational procedure time and reduce the risk of surgical errors which occur when the surgeon’s vision is obscured by excessive blood. Patients benefit through lower healthcare costs, faster recovery and lower risks associated with blood transfusion. Biom’up is a French biotech company founded in 2005 which specialises in collagen-based resorbable medical devices for biosurgery. This project is expected to generate an accumulated revenue of €5 million in 5 years post commercialisation and employ 250 people.
Fields of science
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
69800 SAINT-PRIEST
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.